vs
富兰克林柯维（FC）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是富兰克林柯维的1.2倍（$75.5M vs $64.0M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -7.3%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-1.6M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 2.2%）
富兰克林柯维总部位于美国犹他州盐湖城，是一家专业培训指导企业，面向各类组织与个人提供领导力提升、个人效能成长与业务执行领域的培训及评估服务。公司由富兰克林奎斯特与柯维领导力中心于1997年合并成立，最为人熟知的产品包括富兰克林柯维规划系统等。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
FC vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.2倍
$64.0M
营收增速更快
PBYI
高出35.0%
-7.3%
自由现金流更多
PBYI
多$16.0M
$-1.6M
两年增速更快
PBYI
近两年复合增速
2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.0M | $75.5M |
| 净利润 | $-3.3M | — |
| 毛利率 | 75.5% | 69.3% |
| 营业利润率 | -5.7% | 22.7% |
| 净利率 | -5.1% | — |
| 营收同比 | -7.3% | 27.7% |
| 净利润同比 | -378.5% | — |
| 每股收益（稀释后） | $-0.27 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCPBYI
| Q4 25 | $64.0M | $75.5M | ||
| Q3 25 | $71.2M | $54.5M | ||
| Q2 25 | $67.1M | $52.4M | ||
| Q1 25 | $59.6M | $46.0M | ||
| Q4 24 | $69.1M | $59.1M | ||
| Q3 24 | $84.1M | $80.5M | ||
| Q2 24 | $73.4M | $47.1M | ||
| Q1 24 | $61.3M | $43.8M |
净利润FCPBYI
| Q4 25 | $-3.3M | — | ||
| Q3 25 | $4.4M | $8.8M | ||
| Q2 25 | $-1.4M | $5.9M | ||
| Q1 25 | $-1.1M | $3.0M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $12.0M | $20.3M | ||
| Q2 24 | $5.7M | $-4.5M | ||
| Q1 24 | $874.0K | $-4.8M |
毛利率FCPBYI
| Q4 25 | 75.5% | 69.3% | ||
| Q3 25 | 75.5% | 77.7% | ||
| Q2 25 | 76.5% | 76.5% | ||
| Q1 25 | 76.7% | 77.1% | ||
| Q4 24 | 76.3% | 76.4% | ||
| Q3 24 | 78.1% | 63.9% | ||
| Q2 24 | 76.6% | 77.4% | ||
| Q1 24 | 76.4% | 75.5% |
营业利润率FCPBYI
| Q4 25 | -5.7% | 22.7% | ||
| Q3 25 | 11.1% | 17.6% | ||
| Q2 25 | -3.3% | 12.7% | ||
| Q1 25 | -2.4% | 8.7% | ||
| Q4 24 | 2.1% | 22.6% | ||
| Q3 24 | 21.3% | 27.4% | ||
| Q2 24 | 11.4% | -4.6% | ||
| Q1 24 | 2.4% | -5.3% |
净利率FCPBYI
| Q4 25 | -5.1% | — | ||
| Q3 25 | 6.1% | 16.2% | ||
| Q2 25 | -2.1% | 11.2% | ||
| Q1 25 | -1.8% | 6.5% | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 14.2% | 25.2% | ||
| Q2 24 | 7.8% | -9.6% | ||
| Q1 24 | 1.4% | -11.0% |
每股收益（稀释后）FCPBYI
| Q4 25 | $-0.27 | $0.26 | ||
| Q3 25 | $0.34 | $0.17 | ||
| Q2 25 | $-0.11 | $0.12 | ||
| Q1 25 | $-0.08 | $0.06 | ||
| Q4 24 | $0.09 | $0.40 | ||
| Q3 24 | $0.89 | $0.41 | ||
| Q2 24 | $0.43 | $-0.09 | ||
| Q1 24 | $0.06 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.5M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $54.0M | $130.3M |
| 总资产 | $221.3M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资FCPBYI
| Q4 25 | $17.5M | $97.5M | ||
| Q3 25 | $31.7M | $94.4M | ||
| Q2 25 | $33.7M | $96.0M | ||
| Q1 25 | $40.4M | $93.2M | ||
| Q4 24 | $53.3M | $101.0M | ||
| Q3 24 | $48.7M | $96.7M | ||
| Q2 24 | $36.6M | $96.8M | ||
| Q1 24 | $40.9M | $107.2M |
总债务FCPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益FCPBYI
| Q4 25 | $54.0M | $130.3M | ||
| Q3 25 | $66.9M | $115.3M | ||
| Q2 25 | $65.6M | $104.7M | ||
| Q1 25 | $72.5M | $97.1M | ||
| Q4 24 | $80.6M | $92.1M | ||
| Q3 24 | $83.1M | $71.1M | ||
| Q2 24 | $72.2M | $48.5M | ||
| Q1 24 | $70.8M | $51.0M |
总资产FCPBYI
| Q4 25 | $221.3M | $216.3M | ||
| Q3 25 | $242.9M | $202.9M | ||
| Q2 25 | $218.3M | $194.9M | ||
| Q1 25 | $221.3M | $196.2M | ||
| Q4 24 | $239.9M | $213.3M | ||
| Q3 24 | $261.5M | $220.7M | ||
| Q2 24 | $221.0M | $205.0M | ||
| Q1 24 | $221.9M | $214.1M |
负债/权益比FCPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.0K | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | $14.4M |
| 自由现金流率自由现金流/营收 | -2.5% | 19.1% |
| 资本支出强度资本支出/营收 | 2.7% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $5.9M | $41.7M |
8季度趋势，按日历期对齐
经营现金流FCPBYI
| Q4 25 | $98.0K | $14.4M | ||
| Q3 25 | $9.9M | $9.7M | ||
| Q2 25 | $6.3M | $14.1M | ||
| Q1 25 | $-1.4M | $3.6M | ||
| Q4 24 | $14.1M | $15.6M | ||
| Q3 24 | $21.9M | $11.0M | ||
| Q2 24 | $8.2M | $1.0M | ||
| Q1 24 | $12.8M | $11.2M |
自由现金流FCPBYI
| Q4 25 | $-1.6M | $14.4M | ||
| Q3 25 | $5.7M | $9.7M | ||
| Q2 25 | $4.5M | $14.1M | ||
| Q1 25 | $-2.6M | $3.6M | ||
| Q4 24 | $13.1M | $15.6M | ||
| Q3 24 | $20.8M | $11.0M | ||
| Q2 24 | $7.3M | $1.0M | ||
| Q1 24 | $12.1M | — |
自由现金流率FCPBYI
| Q4 25 | -2.5% | 19.1% | ||
| Q3 25 | 8.0% | 17.7% | ||
| Q2 25 | 6.7% | 26.8% | ||
| Q1 25 | -4.4% | 7.7% | ||
| Q4 24 | 19.0% | 26.4% | ||
| Q3 24 | 24.7% | 13.7% | ||
| Q2 24 | 9.9% | 2.1% | ||
| Q1 24 | 19.8% | — |
资本支出强度FCPBYI
| Q4 25 | 2.7% | 0.0% | ||
| Q3 25 | 5.9% | 0.0% | ||
| Q2 25 | 2.7% | 0.0% | ||
| Q1 25 | 2.1% | 0.1% | ||
| Q4 24 | 1.4% | 0.0% | ||
| Q3 24 | 1.3% | 0.0% | ||
| Q2 24 | 1.2% | 0.0% | ||
| Q1 24 | 1.0% | 0.0% |
现金转化率FCPBYI
| Q4 25 | — | — | ||
| Q3 25 | 2.27× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | 11.98× | — | ||
| Q3 24 | 1.83× | 0.54× | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 14.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
